The Critical Path Institute’s Approach to Precompetitive Sharing and Advancing Regulatory Science

The Coalition Against Major Diseases: Developing Tools for an Integrated Drug Development Process for Alzheimer’s and Parkinson’s Diseases

(2009) K Romero et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Translational Toxicology and the Work of the Predictive Safety Testing Consortium

(2009) WB Mattes et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

The FDA Critical Path Initiative and Its Influence on New Drug Development

(2008) Janet Woodcock et al.   Annual Review of Medicine

The innovative medicines initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients

(2008) A. Jackie Hunter   DRUG DISCOVERY TODAY

Strategic paths for biomarker qualification

(2008) Federico M. Goodsaid et al.   TOXICOLOGY

Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective

(2008) Leonard V. Sacks et al.   TUBERCULOSIS